Tags: Drug.
Midafotel (CPPene; SDZ EAA 494) is a potent competitive antagonist at the NMDA receptor. It was originally designed as a potential therapy for excitotoxicity epilepsy or neuropathic pain. It looked very promising in in vitro trials proving to be a potent competitive antagonist at the NMDA without affecting other receptors. Research continued through to in vivo cat studies where it proved to limit damage after occluding the middle cerebral artery leading to ischaemia.
